Primecap Management Co. CA Sells 94,000 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Primecap Management Co. CA reduced its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 9.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 934,800 shares of the biopharmaceutical company's stock after selling 94,000 shares during the quarter. Primecap Management Co. CA owned approximately 0.31% of Amicus Therapeutics worth $8,806,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of FOLD. KBC Group NV boosted its holdings in Amicus Therapeutics by 44.4% in the 4th quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company's stock worth $96,000 after buying an additional 3,120 shares during the period. Swiss National Bank boosted its stake in shares of Amicus Therapeutics by 0.7% in the fourth quarter. Swiss National Bank now owns 437,500 shares of the biopharmaceutical company's stock worth $4,121,000 after acquiring an additional 3,200 shares during the period. Legacy Capital Group California Inc. grew its position in shares of Amicus Therapeutics by 20.2% during the fourth quarter. Legacy Capital Group California Inc. now owns 23,229 shares of the biopharmaceutical company's stock worth $219,000 after purchasing an additional 3,900 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Amicus Therapeutics during the third quarter worth about $55,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in Amicus Therapeutics by 11.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 63,358 shares of the biopharmaceutical company's stock worth $597,000 after purchasing an additional 6,314 shares in the last quarter.

Remove Ads

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on FOLD shares. Morgan Stanley reaffirmed an "equal weight" rating and set a $12.00 price objective (down from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. Needham & Company LLC reiterated a "hold" rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Wells Fargo & Company dropped their price objective on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a report on Thursday, February 20th. StockNews.com cut Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Thursday, February 20th. Finally, Cantor Fitzgerald reissued an "overweight" rating and set a $21.00 price target on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, Amicus Therapeutics has an average rating of "Moderate Buy" and a consensus price target of $16.75.

Amicus Therapeutics Trading Down 3.6 %

Shares of NASDAQ:FOLD traded down $0.32 during trading on Monday, reaching $8.69. The company's stock had a trading volume of 5,646,678 shares, compared to its average volume of 2,406,177. The firm's 50 day simple moving average is $9.35 and its two-hundred day simple moving average is $10.06. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. Amicus Therapeutics, Inc. has a 12 month low of $8.55 and a 12 month high of $12.65. The stock has a market capitalization of $2.67 billion, a PE ratio of -48.28, a price-to-earnings-growth ratio of 1.51 and a beta of 0.69.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.